Literature DB >> 17031201

Sclerosing cholangitis.

E B Martins1, R W Chapman.   

Abstract

Primary sclerosing cholangitis is a chronic cholestatic disease that may have an autoimmune basis. Most patients have a circulating antineutrophil cytoplasmic antibody that appears to be targeted against a 50-kD nuclear envelope protein. The clinical applications of this antibody have not yet been defined. Other autoantibodies directed against antigens, such as cathepsin G, elastase, and anticardiolipin, may also be detected in some patients. It is suggested that primary sclerosing cholangitis may have a bacterial cause. Helicobacter gene sequences have been detected in liver tissues in primary sclerosing cholangitis. The role of Helicobacter spp and other bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined. Primary sclerosing cholangitis may overlap with autoimmune hepatitis in some cases, although the real prevalence of this association remains to be determined. Many prognostic models have been created, but they lack cross-validation, and their clinical usefulness remains limited. Endoscopic retrograde cholangiography remains the gold standard for diagnosis, but magnetic resonance imaging may be a viable alternative in many cases. Clinical trials with cladibrine, pentoxifylline, and budesonide have failed to demonstrate benefits. Orthotopic liver transplantation remains the only effective treatment.

Entities:  

Year:  2001        PMID: 17031201     DOI: 10.1097/00001574-200109000-00010

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  3 in total

Review 1.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

2.  Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Authors:  Tamas Tornai; David Tornai; Nora Sipeki; Istvan Tornai; Rayan Alsulaimani; Kai Fechner; Dirk Roggenbuck; Gary L Norman; Gabor Veres; Gabriella Par; Alajos Par; Ferenc Szalay; Peter Laszlo Lakatos; Peter Antal-Szalmas; Maria Papp
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

3.  Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.

Authors:  Tamas Tornai; Eszter Palyu; Zsuzsanna Vitalis; Istvan Tornai; David Tornai; Peter Antal-Szalmas; Gary L Norman; Zakera Shums; Gabor Veres; Antal Dezsofi; Gabriella Par; Alajos Par; Peter Orosz; Ferenc Szalay; Peter Laszlo Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.